Last reviewed · How we verify

NCT03532763: INTOC

Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation

Status unknown NA Last updated 29 August 2018
What this trial tests

NA trial testing Tocotrienol-rich fraction in Inflammation in 180 participants. Status unknown.

Timeline
19 April 2018
Primary endpoint
30 June 2019
30 June 2019

Quick facts

Lead sponsorMalaysia Palm Oil Board
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment180
Start date19 April 2018
Primary completion30 June 2019
Estimated completion30 June 2019
Sites1 location across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

Malaysia Palm Oil Board

Who can join

Adults 30 to 60, any sex, with Inflammation or Cardiovascular Risk Factor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to address the anti-inflammatory effect of tocotrienol supplementation in subjects with moderately elevated inflammation. It is hypothesized that 6 months supplementation of tocotrienols will reduce inflammatory markers of subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Inflammation

Currently open trials in the same condition.

Other Malaysia Palm Oil Board trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03532763.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing